U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H38O5
Molecular Weight 382.5341
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of SM-10906

SMILES

CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C[C@@H](CCOCC(O)=O)C[C@H]12

InChI

InChIKey=KCWJAXJEGXEZQC-JKVOQSHXSA-N
InChI=1S/C22H38O5/c1-3-4-5-15(2)10-18(23)6-7-19-20-12-16(8-9-27-14-22(25)26)11-17(20)13-21(19)24/h6-7,15-21,23-24H,3-5,8-14H2,1-2H3,(H,25,26)/b7-6+/t15-,16+,17-,18+,19+,20-,21+/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H38O5
Molecular Weight 382.5341
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 1
Optical Activity UNSPECIFIED

Description

Pimilprost (SM-10902) and its free acid, SM-10906 are new stable 3-oxa-methano prostaglandin (PG) I1 analogs, SM-10902 is a prodrug of SM-10906. SM-10906, but not SM-10902 was demonstrated to be an agonist for IP receptors. SM-10906 was shown to exert its anti-platelet and vasodilatory activities through the increase of the cAMP level. Pimilprost was being developed by Dainippon Sumitomo Pharma (formerly Sumitomo Pharmaceuticals) in Japan for the treatment of skin ulcers. In Japan, an NDA was filed for pimilprost and was awaiting registration. However, development appears to have been discontinued.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
100.0 nM [IC50]
6.3 null [pKi]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
genetically diabetic mice (db/db mice) treated with Pimilprost (SM-10902) ointment (1, 10 and 100 micrograms/g) showed greater decrease in wound lesion area not covered with epidermis and fewer complete healing days than those treated with ointment base
Route of Administration: Transdermal
In Vitro Use Guide
Pimilprost (SM-10902) is a prodrug of SM-10906. SM-10906 dose-dependently stimulated GTP-dependent adenylate cyclase activity in the membrane fraction, the EC50 value being 35 nM. Furthermore, SM-10906 prevented a thrombin-induced increase in the intracellular Ca2+ concentration, the IC50 value being 300 nM. These IC50 and EC50 values are much lower than those of SM-10902.
Substance Class Chemical
Record UNII
NW385A9DRM
Record Status Validated (UNII)
Record Version